Navigation Links
AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
Date:7/14/2008

AMSTERDAM, The Netherlands, July 15 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the start of a collaboration with St. Jude Children's Research Hospital in Memphis, Tennessee, USA, on the development of a gene therapy treatment for Hemophilia B. Under the deal, AMT will receive the exclusive commercial rights to the final product. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially cure this seriously debilitating disease with a single administration of the product.

Hemophilia B is characterized by severe episodes of external and internal bleeding that result in significant morbidity, cause long-term damage in the joints and may be fatal when occurring in tissues like the brain. Current treatments require up to three injections a week to stop or prevent bleeding, which is a burden for young children, may be associated with abnormal blood clotting and does not prevent recurrent bleeding episodes.

Hemophilia B is a rare disease, occurring in 1 in 30,000 people, almost always in males. The total number of patients in Europe and the US is estimated between 35,000 and 40,000.

Important collaboration with leading research institute

Under the agreement AMT will sponsor research in Hemophilia B at St. Jude. Ronald Lorijn, CEO of AMT said: "The importance of this collaboration with renowned St. Jude Children's Research Hospital stretches beyond its scientific and business aspects. This collaboration will bring to these patients the hope that a real cure is on the horizon. Access to the Factor IX gene therapy program perfectly complements our gene therapy platform allowing us to develop an effective and long-lasting therapy for Hemophilia B. Dr. Arthur W. Nienhuis and his group at St. Jude have done very important scientific work on this disease and we really look forward to collabor
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
2. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
3. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Evotec Starts Phase II in Smoking Cessation with EVT 302
6. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
7. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
8. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
9. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
10. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
11. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... ... Solutions, announces today that a second US laboratory is to open in Manhattan, ... with the continued partnership and long-term growth of research and development through collaboration ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently ... The company has added a AS16 Sharples centrifuge to harvest products after fermentation. ... or fungal fermentation process development. , The new centrifuge greatly expands production ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... and macromolecular science at Case Western Reserve University, and ... optical imaging of anisotropic fluids such as liquid crystals, ... techniques. A research paper detailing the team,s findings appeared ... . , The molecules of these fluids, such as ...
... Guidance to $245 Million to $247 Million -, Third Quarter 2008 Highlights:, ... third quarter of 2007 -- Total revenues without Osteocel of $62.5 ... 2007, -- Gross profit of $54.7 million; up 73.2% from ... compared to 82.0% in the third quarter of 2007, -- ...
... Dynamic Alert Limited,(OTC Bulletin Board: DYMC) (the "Company") ... of medical cannabis-based,pharmaceutical products. Today the Company is ... acquire all of the assets of Cannex, a ... and political,activist Steven W. Kubby (http://www.kubby.com ). ...
Cached Biology Technology:Case Western Reserve University researcher improves LCDs with 3-D nanoimaging process 2Case Western Reserve University researcher improves LCDs with 3-D nanoimaging process 3Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... plots in the Northeast and Midwestern United States contain at ... study found. The study across two dozen states from North ... the landscape where invasive plants might take root. "We ... forest inventory had at least one introduced species, but this ...
... related in composition to the active ingredient in marijuana may ... the Journal of Leukocyte Biology shows ... in white blood cells, specifically macrophages, appear to weaken HIV-1 ... which the pharmaceutical properties of cannabis are manifested. Diminishing ...
... the remains of a recent lottery winner having been exhumed ... wonder what they can do to avoid the same fate. ... involving zebrafish suggests that riboflavin, also known as vitamin ... In addition, the report shows that zebrafish are a viable ...
Cached Biology News:In the Northeast, forests with entirely native flora are not the norm 2Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies 2Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning 2
See product name for description....
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Biology Products: